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Neuronal cellsFocal adhesion kinase (FAK), a non-receptor protein kinase, is known to be a phosphatidyl inositol 3-kinase
(PI3K) pathway activator and thus widely implicated in regulation of cell survival and cancer. In recent years
FAK has also been strongly implicated as a crucial regulator of insulin resistance in peripheral tissues like
skeletal muscle and liver, where decrease in its expression/activity has been shown to lead to insulin resis-
tance. However, in the present study we report an altogether different role of FAK in regulation of insulin/
PI3K signaling in neurons, the post-mitotic cells. An aberrant increase in FAK tyrosine phosphorylation was
observed in insulin resistant Neuro-2a (N2A) cells. Downregulation of FAK expression utilizing RNAi mediat-
ed gene silencing in insulin resistant N2A cells completely ameliorated the impaired insulin/PI3K signaling
and glucose uptake. FAK silencing in primary cortical neurons also showed marked enhancement in glucose
uptake. The results thus suggest that in neurons FAK acts as a negative regulator of insulin/PI3K signaling. In-
terestingly, the available literature also demonstrates cell-type speciﬁc functions of FAK in neurons. FAK that
is well known for its cell survival effects has been shown to be involved in neurodegeneration. Along with
these previous reports, present ﬁndings highlight a novel and critical role of FAK in neurons. Moreover, as
this implicates differential regulation of insulin/PI3K pathway by FAK in peripheral tissues and neuronal
cells, it strongly suggests precaution while considering FAK modulators as possible therapeutics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Insulin, in addition to its varied functions in peripheral tissues, has
been found to regulate various key physiological functions in brain,
like energy homeostasis, food intake, reproductive endocrinology,
learning, memory and also life span [1,2]. Insulin enters the brain
through blood brain barrier (BBB) where it also regulates neuronal de-
velopment, survival and synaptic transmission [3]. Dysfunction of the
insulin signaling pathway in brain has been reported to contribute to
hyperphagia, obesity and type 2 diabetes [1,4,5]. Also, currently there
is widening recognition that chronic neurodegenerative disorder
Alzheimer's disease (AD) is closely linked to a state of relative insulin
resistance in the brain, and so AD is also termed as “type 3 diabetes”
[6–9]. Despite these facts themolecularmechanism of insulin resistance
in neurons, the post-mitotic functional unit of brain, remains largely un-
known contrary to that in peripheral tissues like skeletal muscle, liver
and adipose and thus drug development has been non-productive to
treat neuronal insulin resistance and complications associated with it.Sciences, Indian Institute of
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sponsible for integrin signaling, is also known to be an activator of
phosphatidyl inositol 3-kinase (PI3K) pathway and thus widely im-
plicated in regulation of cell survival and cancer [10]. Over the past
few years FAK has been established as a crucial mediator of insulin
signaling in peripheral tissues [10–15]. Our laboratory has implicated
an important role of FAK in the regulation of insulin resistance in pe-
ripheral tissues [12,13]. We reported that tyrosine dephosphorylation
of FAK i.e. decrease in its activity, precedes the development of insulin
resistance in skeletal muscle cells [12]. Downregulation of FAK ex-
pression in C2C12 skeletal muscle cells resulted in impaired insulin
signaling through abrogation of activation and/or expression of sever-
al insulin signaling molecules such as insulin receptor substrate-1
(IRS-1), PI3K, Akt, protein kinase C (PKC), glycogen synthase kinase
3β (GSK-3β), etc., followed by decrease in glucose uptake [12]. Fur-
ther, recently our in vivo study has demonstrated that inhibition of
FAK expression in liver and muscle of mice result in exacerbated insu-
lin signaling and cause hyperglycemia and hyperinsulinemia [13].
FAK-silenced animals were less glucose tolerant and have physiolog-
ical and biochemical parameters similar to that of high-fat-diet
(HFD)-fed insulin resistant animals [13]. Taken together, these ﬁnd-
ings strongly suggest involvement of FAK as a positive regulator of in-
sulin signaling in peripheral tissues where decrease in its expression/
activity leads to insulin resistance.
FAK is also abundantly expressed in neurons [16]. However, role of
FAK in neuronal insulin signaling and resistance has not been
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Fig. 1. Effect of neuronal insulin resistance on FAK tyrosine phosphorylation. N2A cells
were differentiated in serum free medium in the absence of (MF) or chronic presence of
100 nM insulin (MFI) for 3 days. Protein extracts (500 μg) were immunoprecipitated
with anti-FAK antibody, subjected to western immunoblotting and probed with anti-
phospho-tyrosine or anti-FAK antibody. Bars represent relative densitometric values of
pFAK after normalizing with FAK expression (pFAK/FAK). Experiments were repeated
thrice and a representative result is shown. Values are mean±SE. **Pb0.01 compared
with lane 1. Open bars, MF; ﬁlled bars, MFI. IP, Immunoprecipitated; IB, Immunoblotted.
1031A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037deciphered yet. Interestingly, activation of FAK in brain has been im-
plicated in the pathogenesis of AD [17,18], the disease which is in-
creasingly being recognized as a brain-speciﬁc form of diabetes [6].
The present study was aimed to investigate the exact role of FAK in
neuronal insulin resistance, if any, using an in vitro neuronal insulin
resistant model [19] and primary cortical neurons.
2. Materials and methods
2.1. Cell culture
Mouse neuroblastoma cell line, Neuro-2a (N2A) was cultured in
minimum essential medium (MEM) supplemented with 10% FBS
and antibiotics (penicillin 100 IU/ml, streptomycin 100 μg/ml) in 5%
CO2 at 37 °C. Conﬂuent cells were differentiated in an equal mixture
of two serum free media (MCDB 201 and Ham's F-12 medium) in ab-
sence (MF: insulin sensitive) or in chronic presence of 100 nM insulin
(MFI: insulin resistant) for 3 days in presence of 2% dimethyl sulfox-
ide (DMSO) with change of media after every 12 h [19]. Mouse prima-
ry cortical neurons were cultured as described previously [20].
2.2. siRNA transfection
siRNA oligonucleotides were designed and synthesized by Qiagen
GmbH (Germany) to target following cDNA sequences: Nonspeciﬁc
(Scrambled) siRNA, 5′ AATTCTCCGAACGTGTCACGT; FAK siRNA, F1:
5′-TGCAATGGAACGAGTATTAAA, F2: 5′-CAAGAAATAGCTGATCAAGTA.
Cells were transfected with either FAK speciﬁc (F1 or F2, as speciﬁed
in text) or nonspeciﬁc (scrambled) siRNA using RNAifect transfection
reagent (Qiagen GmbH, Germany) in reduced serum Opti-MEM
media as described previously [12].
2.3. Preparation of cell lysates for immunoblotting
N2A cells were transfected with siRNA as indicated and allowed to
differentiate under MF or MFI conditions for 3 days. Cells were then
incubated with or without insulin (100nM) for 30 min [21] and
lysed in cell lysis buffer as described previously [12]. Equal concentra-
tions of all the samples were subjected to SDS-PAGE followed by
western immunoblotting. The immunoblots were quantiﬁed using
Quantity One 1-D analysis software as described previously [12].
2.4. Glucose uptake assay
Glucose uptake assays were performed by a modiﬁed method of
Scheele et al. [22] using [3H]2-deoxyglucose (2-DOG).
2.5. Phosphatidyl inositol 3-kinase (PI3K) activity
PI3K activity associated with IRS-1 was determined with PI3K
ELISA Kit (Echelon Biosciences Inc., SaltLake City, UT, USA) according
to the manufacturer's instructions and as reported previously [12].
2.6. Statistical analysis
All the experiments were performed a minimum of three times
and a representative result is shown. Data are expressed as mean±
SE. Signiﬁcance of difference between two groups (P-values) was cal-
culated by two-tailed unpaired student's t-test. In all the cases Pb0.05
was considered to be statistically signiﬁcant, with Pb0.05 was given *,
while Pb0.01 was given **.
2.7. Materials
Minimum Essential Media (MEM), Nutrient Mixture F-12 Ham,
MCDB 201 medium, bovine albumin (cell culture grade), [3H]2-deoxyglucose were purchased from Sigma Chemical Company (MO,
USA). Fetal bovine serum (FBS)was fromBiological Industries (Kibbutz
Beit, Haemek, Israel). Anti-phospho Akt (Ser473), Anti-phospho Akt
(Thr 308), Anti-Akt, Anti-phospho PKCζ (Thr410/403), Anti-PKCζ,
Anti-phospho GSK3β, Anti-GSK3β and Anti-GLUT4 antibodies were
from Cell Signaling Technology (MA, USA). Anti-FAK antibody was
from Upstate Biotechnology (NY, USA). Anti-phosphotyrosine, Anti-
IRβ, Anti-IRS1 andAnti-Pyk2 antibodieswere from Santa Cruz Biotech-
nology (CA, USA). Anti- α-Tubulin was from Neomarkers (CA, USA).
Bovine insulin was purchased from Calbiochem (CA, USA). Nitrocellu-
lose membranes were procured from Bio-Rad Laboratories (Hercules,
CA, USA). All the other reagents unless attributed speciﬁcally were
from Sigma Chemical Company (MO) or Amresco (OH, USA).
3. Results
3.1. Effect of neuronal insulin resistance on FAK tyrosine phosphorylation
To determine the role of FAK in neuronal insulin resistance, if any,
neuro-2a (N2A) cells were differentiated under insulin-sensitive
(MF) or insulin-resistant (MFI) conditions (Supplementary Fig. 1)
[19] and FAK tyrosine phosphorylation under these conditions was
examined. Cells were lysed, immunoprecipitated with anti-FAK and
subjected to western immunoblotting with anti-phosphotyrosine or
anti-FAK antibodies. As compared to MF, we observed an aberrant in-
crease (~ 500%) in tyrosine phosphorylation of FAK under MFI condi-
tions (Fig. 1, pb0.01), without any change in its protein level (Fig. 1),
suggesting activation of FAK under neuronal insulin resistant
conditions. These ﬁndings emphasize the possible involvement of
FAK in neuronal insulin resistance.
3.2. FAK silencing using RNA interference (RNAi)
To ascertain the role of FAK in neuronal insulin resistance, we
employed RNAi to suppress endogenous FAK levels in N2A cells.
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Fig. 2. Level of FAK expression in FAK-siRNA transfected MF-MFI differentiated N2A cells.
Scrambled or FAK-speciﬁc siRNA transfected N2A cells were differentiated in absence
(MF) or chronic presence of insulin (MFI) for 3 days and stimulated with or without insu-
lin (100nM) for 30 min. Cell lysates were subjected to western immunoblotting and
probed with anti-FAK or anti-Tubulin antibodies. Bar represents relative densitometric
values of FAK expression after normalizing with tubulin expression (FAK/Tubulin). Exper-
iments were repeated thrice and a representative result is shown. Values are mean±SE.
**Pb0.01 compared with lane 1; $$Pb0.01 compared with lane 3; ##Pb0.01 compared
with lane 5; θθPb0.01 compared with lane 7. Open bars, MF; ﬁlled bars, MFI. IB,
Immunoblotted.
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Fig. 3. Effect of FAK downregulation on impaired glucose uptake under neuronal insu-
lin resistance. Scrambled or FAK-speciﬁc siRNA transfected N2A cells were differentiat-
ed in absence (MF) or chronic presence of insulin (MFI) for 3 days and stimulated with
or without insulin (100 nM) for 30 min. Uptake of 2-deoxyglucose (2DOG) was mea-
sured in 40 μg cell lysates. Uptake of each sample was measured in duplicate. Bar rep-
resents relative change in 2-DOG uptake. All the experiments were repeated thrice and
a representative result is shown. Values are mean±SE. **Pb0.01 compared with
lane 1; $$Pb0.01 compared with lane 3; ##Pb0.01 compared with lane 5; θθPb0.01
compared with lane 7. Open bars, MF; ﬁlled bars, MFI.
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Fig. 4. Effect of downregulation of FAK on glucose uptake in mouse primary cortical
neurons. Primary cortical neurons were transfected with scrambled or FAK-speciﬁc
siRNA. (A) Cell lysates were subjected to western immunoblotting and probed with
anti-FAK or anti-Tubulin antibodies (B) Uptake of 2-deoxyglucose (2DOG) was measured
in 40 μg cell lysates. Uptake of each sample wasmeasured in duplicate. Bar represents rel-
ative change in 2-DOG uptake. Experiments were repeated thrice. Values are mean±SE.
**Pb0.01 compared with lane 1. Open bars, Scrambled siRNA transfected primary neu-
rons; ﬁlled bars, FAK-speciﬁc siRNA transfected primary neurons. IB, Immunoblotted.
1032 A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037FAK-speciﬁc siRNA duplexes (denoted as F1 in materials and
methods) showed a dose-dependent silencing of FAK, with maximal
silencing at 150 pmol (data not shown). FAK-speciﬁc siRNA (150
pmol) demonstrated signiﬁcant FAK downregulation (82.0±0.05%)
after normalizing it with similar concentration of scrambled siRNA
(to determine non-speciﬁc silencing) (Supplementary Fig. 2), without
affecting cellular morphology and viability as seen by phase contrast
microscopy (Supplementary Fig. 3) and MTT assay (data not
shown). We next studied the effect of FAK speciﬁc or non-speciﬁc
(scrambled) siRNA transfection on FAK expression under MF and
MFI conditions, with or without insulin stimulation. Data showed
that the level of FAK in FAK-siRNA-transfected cells remained down-
regulated (~80%) under all the conditions as compared to scrambled-
siRNA transfected cells (Fig. 2).
3.3. Effect of FAK downregulation on impaired glucose uptake under neu-
ronal insulin resistance
To assess the functional contribution of altered FAK protein level
in the pathogenesis of neuronal insulin resistance, glucose uptake
was measured in FAK silenced N2A cells differentiated under insulin
sensitive (MF) and insulin resistant (MFI) conditions, with or without
insulin stimulation. Insulin-stimulated glucose uptake of chronically
insulin treated cells (MFI) was completely impaired as compared to
control cells (MF) (Fig. 3, lane 5 and lane 7 vs. lane 1 and lane 3).
FAK silencing under the MFI condition resulted in marked enhance-
ment (71.6±0.05%) of insulin-stimulated glucose uptake (Fig. 3,
lane 8 vs. lane 7, pb0.01), resulting in comparable glucose uptake to
that observed under insulin-sensitive (MF) conditions (Fig. 3, lane8 vs. lane 3). Under the basal MFI condition also FAK silencing led to
signiﬁcant enhancement (33.3±0.04%) of glucose uptake (Fig. 3,
lane 6 vs. lane 5, pb0.01). Silencing FAK under insulin-sensitive con-
ditions (MF) led to additional increases in glucose uptake as
1033A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037compared to respective scrambled-siRNA transfected controls (Fig. 3,
pb0.01). The results were further conﬁrmed by silencing FAK using
another FAK-speciﬁc siRNA (denoted as F2 in materials and methods)
in N2A cells differentiated under MF and MFI conditions, with or
without insulin stimulation. It also demonstrated nearly same in-
crease in glucose uptake (data not shown). The results thus suggest
that FAK silencing has insulin-sensitizing effects in neuronal cells
and it could effectively ameliorate the impaired glucose uptake in
insulin resistant neuronal cells.Fig. 5. Effect of FAK downregulation on impaired insulin signaling under neuronal insulin re
absence (MF) or chronic presence of insulin (MFI) for 3 days and stimulated with or withou
anti-IRβ antibody, subjected to western immunoblotting and probed with anti-phosphotyr
normalizing with IRβ expression (pIRβ/IRβ). (B) Cell lysates (500 μg) were immunoprecipi
anti-phospho-tyrosine or anti- IRS1 antibodies. Bar represents relative densitometric va
(500 μg) were immunoprecipitated with anti-IRS1 antibody and PI3K activity was measu
were subjected to western immunoblotting and probed with anti-phospho Akt (Ser473)
after normalizing with Akt expression [pAkt(Ser473)/Akt]. (E) Cell lysates were subjecte
GSK3β antibodies. Bar represents relative densitometric values of pGSK3β (Ser9) after nor
western immunoblotting and probed with anti-phospho PKCζ or anti-Tubulin antibodies. B
pression (pPKCζ /Tubulin). (G) The low-density microsome (LDM) and plasma fractions (PM
anti-Tubulin antibodies. Bar represents relative densitometric values of GLUT4 expression in
result is shown. Values are mean±SE. **Pb0.01 compared with lane 1; *Pb0.05 compared w
compared with lane 5; θθPb0.01 compared with lane 7. Open bars, MF; ﬁlled bars, MFI. IP,3.4. Effect of FAK downregulation on glucose uptake in primary cortical
neurons
To further examine the functional relevance of FAK in regulating
neuronal insulin signaling, we measured glucose uptake in FAK
silenced mouse primary cortical neurons. Consistent with the results
obtained in N2A cells, FAK silencing in primary cortical neurons
(Fig. 4A) showed marked enhancement (68.9±0.62%) in glucose up-
take, as compared to scrambled-siRNA transfected primary neuronssistance. Scrambled or FAK-speciﬁc siRNA transfected N2A cells were differentiated in
t insulin (100 nM) for 30 min. (A) Cell lysates (500 μg) were immunoprecipitated with
osine or anti-IRβ antibodies. Bar represents relative densitometric values of pIRβ after
tated with anti-IRS1 antibody, subjected to western immunoblotting and probed with
lues of pIRS1 after normalizing with IRS1 expression (pIRS1/IRS1). (C) Cell lysates
red. Bar represents relative change in IRS1 associated PI3K activity. (D) Cell lysates
or anti-Akt antibodies. Bar represents relative densitometric values of pAkt (Ser473)
d to western immunoblotting and probed with anti-phospho GSK3β (Ser9) or anti-
malizing with GSK3β expression (pGSK3β/GSK3β). (F) Cell lysates were subjected to
ar represents relative densitometric values of pPKCζ after normalizing with tubulin ex-
) were isolated, subjected to western immunoblotting and probed with anti-GLUT4 or
LDM and PM fractions. All the experiments were repeated thrice and a representative
ith lane 1; $$Pb0.01 compared with lane 3; ##Pb0.01 compared with lane 5; #Pb0.05
Immunoprecipitated; IB, Immunoblotted.
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Fig. 5 (continued).
1034 A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037(Fig. 4B, pb0.01), emphasizing a novel role of FAK as a negative
regulator of neuronal insulin signaling.
3.5. Effect of FAK downregulation on impaired insulin signaling under
neuronal insulin resistance
We next examined the potential molecular mechanism that might
underlie the protection from neuronal insulin resistance conferred bydownregulation of FAK levels, by testing insulin signal transduction
cascade in FAK-speciﬁc or scrambled siRNA transfected N2A cells
differentiated under insulin sensitive (MF) and insulin resistant
(MFI) conditions, with or without insulin stimulation.
A marked reduction (93.1±2.1%) in insulin-stimulated tyrosine
phosphorylation of IRβ under MFI condition was observed (Fig. 5A,
lane 5 and lane 7 vs. lane 1 and lane 3). FAK silencing under MFI con-
dition resulted in ~450% increase in insulin-stimulated tyrosine
1035A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037phosphorylation of IRβ (Fig. 5A, lane 8 vs. lane 7, pb0.01), thereby
greatly improving the impaired IRβ tyrosine phosphorylation
(Fig. 5A, lane 8 vs. lane 3). Under insulin sensitive condition (MF)
FAK silencing showed an increment of 58.3±2.0% in insulin-
stimulated tyrosine phosphorylation of IRβ, as compared to
scrambled-siRNA transfected cells stimulated with insulin (Fig. 5A,
lane 4 vs. lane 3, pb0.01). In accordance to glucose uptake data, FAK
silencing alone was able to enhance tyrosine phosphorylation of IRβ
as was evident by its increment of 284.7±0.60% and 718.3±1.2% at
the basal level, in cells differentiated under MF and MFI condition, re-
spectively, as compared to respective scrambled-siRNA transfected
controls (Fig. 5A, lane 2 vs. lane 1 and lane 6 vs. lane 5, respectively,
pb0.01). Expression of IRβ was unaltered due to FAK silencing
(Fig. 5A).
The impaired insulin-stimulated IRS1 tyrosine phosphorylation
observed under MFI condition (Fig. 5B) was also effectively amelio-
rated by FAK silencing, as evident by an increase of 92.7±0.9% in
insulin-stimulated tyrosine phosphorylation of IRS1 as compared to
scrambled-siRNA transfected MFI cells stimulated with insulin
(Fig. 5B, lane 8 vs. lane 7, pb0.01). This led to comparable IRS1 tyro-
sine phosphorylation to that observed under insulin-sensitive (MF)
conditions (Fig. 5B, lane 8 vs. lane 3). However, FAK silencing under
MF condition did not show any further increment in its insulin-
stimulated tyrosine phosphorylation as compared to scrambled-
siRNA transfected insulin-stimulated MF control (Fig. 5B, lane 4 vs.
lane 3), probably due to the saturable activation of IRS1. FAK silencing
increased the basal IRS1 tyrosine phosphorylation by 72.5±0.62%
and 44.0±0.73%, in cells differentiated under MF and MFI condition,
respectively, as compared to respective scrambled-siRNA transfected
controls (Fig. 5B, pb0.05). Expression of IRS1 was unaltered by FAK
silencing (Fig. 5B).
Parallel to impaired tyrosine phosphorylation of IRS1, an impaired
insulin-stimulated IRS1-associated PI3K activity was observed under
MFI condition (Fig. 5C). Moreover, FAK silencing under MFI condition
signiﬁcantly restored (increased by 80.2±0.21%) its activity to that of
insulin-stimulated MF control (Fig. 5C, lane 8 vs. lane 3). FAK silenc-
ing under MF condition did not cause any signiﬁcant increment in
insulin-stimulated PI3K activity associated to IRS1, as compared to
scrambled-siRNA transfected insulin-stimulated MF control
(Fig. 5C). Silencing of FAK increased the basal IRS1-associated PI3K
activity by 33.0±0.04% and 35.2±0.14%, in cells differentiated
under MF and MFI conditions, respectively, as compared to respective
scrambled-siRNA transfected controls (Fig. 5C, pb0.01).
PI3K activates several PIP3-dependent serine/threonine kinases;
one of them is Akt, which gets activated by its phosphorylation at
Ser473. Insulin-induced Akt phosphorylation was found to be im-
paired under MFI condition (Fig. 5D). FAK silencing markedly in-
creased (~280%) insulin-stimulated Akt phosphorylation at Ser473
under insulin- resistant conditions (MFI) as compared to scrambled-
siRNA transfected MFI cells stimulated with insulin (Fig. 5D, lane
8 vs. lane 7, pb0.01), thereby signiﬁcantly ameliorating its impaired
phosphorylation (Fig. 5D). Under insulin sensitive condition (MF),
FAK silencing further increased insulin-stimulated Akt phosphoryla-
tion by 37.8±0.79% (Fig. 5D, pb0.01). FAK silencing also increased
the basal Akt phosphorylation by 293±0.26% and 131±0.24%, in
cells differentiated under MF and MFI conditions, respectively, as
compared to respective scrambled-siRNA transfected controls
(Fig. 5D, pb0.01). Expression of Akt was unaltered by FAK downregu-
lation (Fig. 5D).
One of the most prevalent downstream targets of Akt is GSK3β
which gets inhibited by Akt mediated phosphorylation at serine 9.
The inhibition of GSK3β activity is a key regulatory mechanism for ac-
tivation of glycogen synthase (GS) leading to glycogen synthesis. Si-
lencing FAK also resulted in marked amelioration of insulin-
stimulated GSK3β phosphorylation at Ser9 (increased by 109.2±
0.13%) under the insulin-resistant conditions (MFI) as compared toscrambled-siRNA transfected MFI cells stimulated with insulin
(Fig. 5E, lane 8 vs. lane 7, pb0.01). The extent of insulin-stimulated
inhibition of GSK3β was close to that observed in insulin sensitive
cells (MF) (Fig. 5E, lane 8 vs. lane 3, pb0.01). Under MF, FAK silencing
further increased the insulin-stimulated GSK3β phosphorylation by
31.9±0.14% (Fig. 5E, pb0.01). It increased the basal phosphorylation
of GSK3β by 65.0±0.06% and 39.8±0.10%, in cells differentiated
under MF and MFI condition, respectively, compared to respective
scrambled-siRNA transfected controls (Fig. 5E, pb0.01). The data
therefore suggests anabolism between enhanced glucose uptake and
glycogen synthesis as a result of increased GSK3β phosphorylation
due to FAK silencing.
Previously PKC has been demonstrated to regulate FAK-mediated
glucose uptake in skeletal muscle [12]. Thus effect of FAK silencing
on PKCζ activation was determined in N2A cells differentiated
under MF and MFI condition. Insulin-induced PKCζ activation was
found to be impaired under MFI condition (Fig. 5F). FAK silencing
led to complete restoration (increased by 122.3±0.10%) of the im-
paired insulin-stimulated PKCζ phosphorylation under MFI condition
(Fig. 5F, lane 8 vs. lane 7, pb0.01). Also, FAK downregulation under
insulin sensitive (MF) conditions led to marked increase in PKCζ
phosphorylation (Fig. 5F).
GLUT4, an insulin responsive glucose transporter in neuronal cells
[23], translocation to plasma membrane was found to be impaired
under insulin resistant (MFI) condition as evident by GLUT4 in-
creased levels in cytosolic (LDM) (Fig. 5G, lane 3 vs. lane 1, pb0.01)
and decreased level in the plasma membrane (PM) fractions
(Fig. 5G, lane 7 vs. lane 5, pb0.01) under insulin-stimulated MFI con-
dition. Silencing FAK under MFI condition resulted in marked increase
(160.2±0.08%) in insulin-stimulated GLUT4 translocation to plasma
membrane (Fig. 5G, lane 8 vs. lane 7, pb0.01), indicating that FAK
negatively regulates GLUT4 translocation. GLUT4 expression was
same under all conditions (data not shown). Data thus demonstrate
that FAK regulates glucose uptake under neuronal insulin resistance
by differentially regulating the translocation of GLUT4 molecules.
Overall, these results indicate that FAK negatively regulates neuro-
nal insulin resistance by suppressing activation of IR, IRS1, PI3K, Akt,
PKC, GLUT4 translocation and glucose uptake and its downregulation
could effectively ameliorate neuronal insulin resistance. This is in
contrast to its role in regulation of insulin signaling in peripheral
tissues.
4. Discussion
The present study provides evidences that show a direct correla-
tion between FAK activation and impairment of insulin actions in
neuronal cells. The study demonstrates a novel role for FAK as a neg-
ative regulator of the insulin/PI3K signalling pathway. The conclusion
is based on the following ﬁndings: (1) an increase in FAK activity was
observed in insulin resistant N2A cells, (2) downregulation of FAK
expression in insulin resistant N2A cells effectively ameliorated
impaired insulin/PI3K signaling and glucose uptake, and (3) downre-
gulation of FAK expression in mouse primary cortical neurons led to
marked increase in glucose uptake.
FAK has been known to be a PI3K activator and thus also widely
implicated in regulation of cell survival pathways and cancer [24].
Previous ﬁndings in peripheral tissues like skeletal muscle and liver
strongly suggested involvement of FAK as a positive regulator of insu-
lin signaling where decrease in its expression/activity leads to insulin
resistance by abrogation of activation and/or expression of several in-
sulin signaling molecules, followed by decrease in glucose uptake
[11–13]. However, here an altogether different role of FAK in regula-
tion of insulin resistance in neurons is being reported. FAK is unex-
pectedly found to be involved in impairment of insulin signaling
and glucose metabolism in neurons. The involved molecular mecha-
nisms of FAK-mediated negative regulation of neuronal insulin
1036 A. Gupta et al. / Biochimica et Biophysica Acta 1822 (2012) 1030–1037resistance include impairment of IRβ, IRS1, PI3K, PKCζ and Akt activa-
tion, followed by impaired GLUT4 translocation to the plasma mem-
brane and thus resulting in impaired glucose uptake. The
mechanism also involved activation of GSK3β, implying negative reg-
ulation of glycogen synthesis by FAK in neurons. In hepatocytes and
skeletal muscle FAK has been implicated in positive regulation of gly-
cogen synthesis [10,11]. Moreover, a signiﬁcant decrease of FAK tyro-
sine phosphorylation has been reported in insulin resistant C2C12
skeletal muscle, which has been shown to precede development of in-
sulin resistance in these cells [12]. A similar decrease has also been
reported in skeletal muscles from insulin-resistant Sprague–Dawley
rats fed on HFD diet [12]. Decrease in FAK activity has also been
reported to precede TNF-α mediated insulin resistance in liver [25].
In adipocytes also FAK has been found to positively regulate glucose
uptake [26]. Thus FAK-mediated negative regulation of insulin resis-
tance appears to be speciﬁc to neurons.
The FAK that is expressed in neurons has been reported to be quite
different from those expressed in non-neuronal cells in various as-
pects (described below); though the functional consequences of
these differences are not much known: (1) FAK exists in various
spliced isoforms that were conserved during evolution and are exclu-
sively or preferentially found in the CNS [27–30]. Several of the splice
variants predict the insertion of short peptides in the coding se-
quence, a fact that accounts for the higher apparent molecular weight
of FAK in brain than in other tissues [29,31]. Neurons mostly express
FAK +6,7 isoform (number indicates the length of peptide in amino
acids encoded by additional exons) [32], (2) The presence of these ad-
ditional exons has been shown to dramatically increase the autopho-
sphorylation of FAK in unstimulated transfected COS7 cells as
compared to isoform without these additional exons (i.e. non-
neuronal isoform) [27,29,32]. Though it is important to note that
autophosphorylation of this neuronal isoform of FAK is tightly regu-
lated in vivo and increases dramatically only in response to some ex-
tracellular messengers or stress [31,33,34]. The contrast between the
levels of phosphorylation of neuronal isoform of FAK in transfected
non-neuronal cells (COS7) and in nervous system suggests that spe-
ciﬁc regulatory mechanisms controling FAK activation exists in neu-
rons [32], (3) FAK is expressed at very high levels in the brain but
in contrast to non-neural cells, FAK is not restricted to focal adhesion
contacts only. FAK is distributed throughout the neuron including the
cell body, dendritic tree, and axon [16,31,35]. This suggests that FAK
has different mechanisms for subcellular localization in neural cells
and as a consequence has novel targets [35], (4) In neurons which
mostly expresses FAK +6,7 isoform, phosphorylation of Tyr397 (a
critical residue for activation and function of FAK) by Src-family ki-
nases, which normally lead to FAK activation and thus triggering sev-
eral signaling cascades, may not be possible [32]; pointing towards an
additional difference with the ubiquitous isoforms, (5) FAK has been
associated with protective (anti-apoptotic) signaling [36,37]; howev-
er, in neurons its activation has been shown to lead to cell death [17].
Neurons have been classically recognized as post-mitotic cells, and it
is suggested that activated FAK may mediate cell cycle activation
thereby leading to neurodegeneration [18].
These observations raise the question of speciﬁc functions of neu-
ronal FAK. Our present ﬁndings demonstrates that in contrast to pe-
ripheral tissues (where FAK acts as a positive regulator of insulin/
PI3K signaling), FAK in neurons acts as a negative regulator of insu-
lin/PI3K signaling where increase in its activity precedes develop-
ment of neuronal insulin resistance. It is to be noted that the
increased phosphorylation of FAK under neuronal insulin resistance
is demonstrated in N2A cells. It would be interesting and more sup-
porting to test the effect in primary neurons, which has not been un-
dertaken in this study. A separate experimental program has been
initiated to generate insulin resistance in primary neurons to address
various important questions along with this issue. We anticipate that
this cell type speciﬁc function of FAK is due to the particular isoformexclusively expressed in neurons which might be in some way rele-
vant to the neuronal physiology (like its post-mitotic nature). Future
studies with various splice variants of FAKwould be interesting in this
regard. Interestingly, similar to our observations an aberrant increase
in FAK phosphorylation is observed in chronic neurodegenerative
disorder, Alzheimer's disease (AD) [17,18,38,39]. There is widening
recognition that neuronal insulin resistance acts as the mediator of
AD. AD is being referred as brain-speciﬁc form of diabetes and even
termed as “type 3 diabetes” [6,8,9]. Our ﬁnding that FAK in neurons
inhibits insulin/PI3K pathway i.e. the route which is reported to be
the vital promoter of cell survival, supports the observation of FAK's
involvement in AD-type neurodegeneration and highlights a crucial
role of FAK in linking the two pathophysiological states.
The highly FAK related protein, Pyk2/RAFTK, is known to compen-
sate for loss of FAK function in some cell types [40]. Pyk2/RAFTK is
highly expressed in the brain and in particular, the hippocampus.
However, in contrast to the non-neuronal cell types the regulation
of these two related kinases (FAK and Pyk2) appear to be very distinct
in the neuronal systems [27,33,41], suggesting that these two homol-
ogous tyrosine kinases have different functions in the nervous system
[27]. This differential regulation of FAK and Pyk2 in nervous system
has been suggested to be due to their localization to different cellular
compartments and to their different modes of activation [27,41]. We
also observed no signiﬁcant change in the levels of Pyk2 with FAK
downregulation as compared to the conrol siRNA transfected cells
(Supplementary Fig. 4).
Summing up, the present ﬁndings provide a “neuronal cell-type
speciﬁc” participating molecular mechanism of insulin resistance,
where activation of FAK results in impairment of insulin/PI3K signal-
ing and glucose metabolism. Importantly, based on the positive role
of FAK in regulating peripheral insulin resistance, chemical entities
that act as activator of FAK has been previously proposed as therapeu-
tic strategy for pathophysiological condition of insulin resistance;
however, present ﬁndings suggest a note of caution. Such modulators
should be designed in such a way that it should not impart neuronal
insulin resistance and complications associated with it, including AD.
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